MedPeer (FRA:9UN) Research & Development: €0.00 Mil (TTM As of Mar. 2025)


FRA:9UN MedPeer Inc FRA:9UN
18 GF Score
Price €3.66
View Full Analysis

What is MedPeer Research & Development?

MedPeer FRA:9UN -0.54% 18 Research & Development is €0.00 Mil as of Mar. 2025. GuruFocus rates FRA:9UN with a GF Score™ of 18/100.

Research & Development is the aggregate amount of research and development expenses during the year. MedPeer's Research & Development for the three months ended in Mar. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00 Mil.

MedPeer  (FRA:9UN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

MedPeer Research & Development Related Terms

MedPeer Research & Development Historical Data

* Premium members only.

The historical data trend for MedPeer's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedPeer Research & Development Chart

MedPeer Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MedPeer Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:9UN
18GF Score
MedPeer Inc FRA:9UN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MedPeer Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
MedPeer (FRA:9UN) has a Research & Development of €0.00 Mil as of Mar. 2025. Research and development expense is the total cost for research and development activities. View historical data on MedPeer and its competitors.
Is MedPeer's Research & Development too high?
MedPeer's current Research & Development is €0.00 Mil. Overall, MedPeer has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does MedPeer's Research & Development compare to DRIO and FORA?
MedPeer's Research & Development of €0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on MedPeer and its competitors. MedPeer's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedPeer stock overvalued right now?
MedPeer (FRA:9UN) has a current Research & Development of €0.00 Mil. The current Research & Development is €0.00 Mil. MedPeer's overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For MedPeer (FRA:9UN), the current Research & Development is €0.00 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedPeer Business Description

Address 2-16-5 Shibuya Manulife Place Building, Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002
MedPeer Inc provides online support for healthcare professionals. The company provides clinical and career support business for doctors, Marketing support for enterprises and advertisement/research business and manages medical community site "MedPeer" for doctors.
18GF Score

Get the complete analysis for FRA:9UN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.66
Price